Table 1.
Clinical and pathological characteristics of the study population (n = 217 breast lesions).
| Variable | BC (n = 217) | Variable | BC (n = 217) |
|---|---|---|---|
| Age at diagnosis | 52 ± 11 [27–80] | Ki67 at biopsy | |
| Hormonal status | ≤14% | 62 (29.0%) | |
| Pre-menopause | 99 (45.8%) | >14% | 152 (71.0%) |
| Menopause | 117 (54.2%) | Breast cCR after NACT | |
| NACT regimen | No | 164 (77.0%) | |
| Type 1 | 59 (27.2%) | Yes | 49 (23.0%) |
| Type 2 | 63 (29.0%) | Type of surgery | |
| Type 3 | 82 (37.8%) | Conservative surgery | 101 (46.5%) |
| Others | 13 (6.0%) | Mastectomy | 116 (53.5%) |
| Clinical tumor stage (cT) | Axillary dissection | ||
| 1 | 43 (19.9%) | No | 41 (18.9%) |
| 2 | 119 (55.1%) | Yes | 176 (81.1%) |
| 3 | 23 (10.7%) | SLN biopsy | |
| 4 | 31 (14.3%) | No | 140 (64.5%) |
| Clinical node stage (cN) | Yes | 77 (35.5%) | |
| 0 | 106 (49.1%) | Breast pCR | |
| 1 | 85 (39.3%) | No | 134 (61.7%) |
| 2 | 19 (8.8%) | Yes | 83 (38.3%) |
| 3 | 6 (2.8%) | Radiotherapy | |
| Histological type at biopsy | No | 68 (31.3%) | |
| Ductal | 184 (84.8%) | Yes | 149 (68.7%) |
| Lobular | 30 (13.8%) | Hormonal therapy | |
| Unknown | 3 (1.4%) | No | 66 (30.4%) |
| Multifocality | Yes | 151 (69.6%) | |
| No | 167 (77.0%) | NLR | 3.3 ± 2.6 [0.9–17.1] |
| Yes | 50 (23.0%) | PLR | 179.1 ± 114.2 [43.5–974.5] |
| Grading at biopsy | MLR | 0.3 ± 0.2 [0.1–1.6] | |
| I | 5 (2.3%) | PIV | 474.4 ± 573.9 [46.3–4964.5] |
| II | 136 (63.9%) | Death | |
| III | 72 (33.8%) | No | 200 (92.2%) |
| Biological portrait at biopsy | Yes | 17 (7.8%) | |
| ER+/HER2- | 81 (37.7%) | Follow-up (months) | 44 ± 18 [3–60] |
| ER+/HER2+ | 66 (30.7%) | DM | |
| ER-/HER2+ | 32 (14.9%) | No | 170 (78.3%) |
| ER-/HER2- | 36 (16.7%) | Yes | 47 (21.7%) |
| Progesteron receptor at biopsy | Time to DM (months) | 40 ± 20 [0–60] | |
| Negative | 87 (40.5%) | ||
| Positive | 128 (59.5%) |